索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]孟颖 庞萌 刘志辉.儿茶酚胺敏感性多行性室性心动过速的研究进展[J].国际心血管病杂志,2019,01:8-11,25.
点击复制

儿茶酚胺敏感性多行性室性心动过速的研究进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2019年01期
页码:
8-11,25
栏目:
综述
出版日期:
2019-02-20

文章信息/Info

Title:
-
作者:
孟颖 庞萌 刘志辉
261031 潍坊医学院神经病学教研室(孟颖); 261031 潍坊医学院附属医院神经内科(庞萌,刘志辉)
Author(s):
-
关键词:
儿茶酚胺敏感性多形性室性心动过速;  晕厥;  猝死;  肾上腺素能β受体拮抗剂;  遗传学
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2019.01.003
文献标识码:
-
摘要:
儿茶酚胺敏感性多形性室性心动过速(CPVT)是一种由心肌钙离子失调引起的罕见遗传性离子通道病,其特征是由交感肾上腺系统兴奋诱发的多形性室性心动过速,患者可表现为晕厥甚至心源性猝死。约56%的CPVT患者存在RyR2或CASQ2基因突变,该突变可导致心肌细胞肌质网的钙泄露,继而引起延迟后除极和触发冲动,但仍有近一半的患者病因未明。儿童、青少年进行体育锻炼或情绪激动时突发晕厥,应高度怀疑CPVT。β受体阻滞剂可有效减少室性心动过速的发作,既往有心脏骤停病史的患者,可置入心脏转复除颤器。目前的治疗方法还有交感神经节切除术、射频消融术等,基因治疗有可能成为未来的治疗方向。
Abstract:
-

参考文献/References


[ 1 ] Velcea AE, Siliste C, Vinereanu D. Catecholaminergic polymorphic ventricular tachycardia—looking to the future[J]. Maedica(Buchar), 2017, 12(4):306-310.
[ 2 ] Roston TM, Vinocur JM, Maginot KR, et al. Catecholaminergic polymorphic ventricular tachycardia in children: an analysis of therapeutic strategies and outcomes from an international multicenter registry[J]. Circ Arrhythm Electrophysiol, 2015, 8(3):633-642.
[ 3 ] Swan H, Piippo K, Viitasalo M, et al. Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts[J]. J Am Coll Cardiol, 1999, 34(7):2035-2042.
[ 4 ] 黄雷, 刘超, 侯一丁, 等. Ryanodine受体2和肌集钙蛋白2基因突变与儿茶酚胺敏感性多形性室性心动过速[J]. 广东医学, 2013, 34(8):1297-1299.
[ 5 ] Lahat H, Pras E, Olender T, et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel[J]. Am J Hum Genet, 2001, 69(6):1378-1384.
[ 6 ] Xiong J, Liu X, Gong Y, et al. Pathogenic mechanism of a catecholaminergic polymorphic ventricular tachycardia causing-mutation in cardiac calcium release channel RyR2[J]. J Mol Cell Cardiol, 2018, 117:26-35.
[ 7 ] 葛庆, 袁越, 杜军保, 等. 中国儿茶酚胺敏感性多形性室性心动过速患者RyR2基因突变分析[J]. 中国心脏起搏与心电生理杂志, 2014, 28(1):24-28.
[ 8 ] Manno C, Figueroa LC, Gillespie D, et al. Calsequestrin depolymerizes when calcium is depleted in the sarcoplasmic reticulum of working muscle[J]. Proc Natl Acad Sci U S A, 2017, 114(4):E638-E647.
[ 9 ] Roston TM, Cunningham TC, Sanatani S. Advances in the diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia[J]. Cardiol Young, 2017, 27(S1): S49-S56.
[10] Rooryck C, Kyndt F, Bozon D, et al. New family with catecholaminergic polymorphic ventricular tachycardia linked to the triadin gene[J]. J Cardiovasc Electrophysiol, 2015, 26(10):1146-1150.
[11] Pérez-Riera AR, Barbosa-Barros R, De Rezende Barbosa MPC, et al. Catecholaminergic polymorphic ventricular tachycardia, an update[J]. Ann Noninvasive Electrocardiol, 2018, 23(4):e12512.
[12] Celiker A, Erdogˇan I, Karagöz T, et al. Clinical experiences of patients with catecholaminergic polymorphic ventricular tachycardia[J]. Cardiol Young, 2009, 19(1):45-52.
[13] Behere SP, Weindling SN. Catecholaminergic polymorphic ventricular tachycardia: an exciting new era[J]. Ann Pediatr Cardiol, 2016, 9(2):137-146.
[14] Kozlovski J, Ingles J, Connell V, et al. Delay to diagnosis amongst patients with catecholaminergic polymorphic ventricular tachycardia[J]. Int J Cardiol, 2014, 176(3): 1402-1404.
[15] Van der Werf C, Wilde AA. Catecholaminergic polymorphic ventricular tachycardia: disease with different faces[J]. Circ Arrhythm Electrophysiol, 2015, 8(3):523-525.
[16] 张萍. 儿茶酚胺敏感性多形性室速心电图特征[J]. 临床心电学杂志, 2014, 23(1):14-17.
[17] Sy RW, Gollob MH, Klein GJ, et al. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia[J]. Heart Rhythm, 2011, 8(6):864-871.
[18] Priori SG, Wilde AA, Horie M, et al. Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes[J]. Europace, 2013, 15(10):1389-1406.
[19] Marjamaa A, Hiippala A, Arrhenius B, et al. Intravenous epinephrine infusion test in diagnosis of catecholaminergic polymorphic ventricular tachycardia[J]. J Cardiovasc Electrophysiol, 2012, 23(2):194-199.[20] 中华心血管病杂志编辑委员会心律失常循证工作组. 遗传性原发性心律失常综合征诊断与治疗中国专家共识[J]. 中华心血管病杂志, 2015, 43(1):5-21.
[21] Tofield A. Hikaru Sato and Takotsubo cardiomyopathy[J]. Eur Heart J, 2016, 37(37):2812.
[22] Templin C, Ghadri JR, Diekmann J, et al. Clinical features and outcomes of takotsubo(stress)cardiomyopathy[J]. N Engl J Med, 2015, 373(10):929-938.
[23] Miyake CY, Asaki SY, Webster G, et al. Circadian variation of ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia[J]. JACC Clin Electrophysiol, 2017, 3(11):1308-1317.
[24] 洪葵, 刘欣, 胡大一. 2013HRS/EHRA/APHRS 遗传性心律失常综合征患者诊断和治疗专家共识解读[J]. 中华心血管病杂志, 2013, 41(11):978-981.
[25] Leren IS, Saberniak J, Majid E. Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with β1-selective β-blockers in patients with catecholaminergic polymorphic ventricular tachycardia[J]. Heart Rhythm, 2016, 13(2):433-440.
[26] Katz G, Khoury A, Kurtzwald E, et al. Optimizing catecholaminergic polymorphic ventricular tachycardia therapy in calsequestrin-mutant mice[J]. Heart Rhythm,2010,7(16):76-82.
[27] Alcalai R, Wakimoto H, Arad M, et al.Prevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation[J]. J Cardiovasc Electrophysiol, 2011, 22(3):316-324.
[28] Smith GL, MacQuaide N. The direct actions of flecainide on the human cardiac ryanodine receptor: keeping open the debate on the mechanism of action of local anesthetics in CPVT[J]. Circ Res, 2015, 116(8):1284-1286.
[29] Watanable H, Chopra N,Laver D, et al. Flecainide prevents catecholamiergic polymorphic ventricular tachycardia in mice and humans[J]. Nat Med, 2009, 15(4):380-383.
[30] Padfield GJ, AlAhmari L, Lieve KV, et al. Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of β-blockade[J]. Heart Rhythm, 2016, 13(2): 609-613.
[31] De Ferrari GM, Dusi V, Spazzolini C, et al. Response to letters regarding article, "clinical management of catecholaminergic polymorphic ventricular tachycardia: the role of left cardiac sympathetic denervation"[J]. Circulation, 2016, 133(4):e366-e367.
[32] Olde Nordkamp LR, Driessen AH, Odero A, et al. Left cardiac sympathetic denervation in the Netherlands for the treatment of inherited arrhythmia syndromes[J]. Neth Heart J, 2014, 22(4):160-166.
[33] Hofferberth SC, Cecchin F, Loberman D, et al. Left thoracoscopic sympathectomy for cardiac denervation in patients with life-threatening ventricular arrhythmias[J]. J Thorac Cardiovasc Surg, 2014, 147(1):404-409.
[34] Yu WS, Kim TH, Suh JW, et al. Thoracoscopic left cardiac sympathetic denervation for a patient with catecholaminergic polymorphic ventricular tachycardia and recurrent implantable cardioverter-defibrillator shocks[J]. Korean J Thorac Cardiovasc Surg, 2015, 48(3):220-224.
[35] Kaneshiro T, Naruse Y, Nogami A, et al. Successful catheter ablation of bidirectional ventricular premature contractions triggering ventricular fibrillation in catecholaminergic polymorphic ventricular tachycardia with RyR2 mutation[J]. Circ Arrhythm Electrophysid, 2012, 5(1):e14-e17.
[36] Hajjar RJ, Lyon AR. Gene therapy for the treatment of catecholaminergic polymorphic ventricular tachycardia[J].Circulation, 2014, 129(25):2633-2635.

备注/Memo

备注/Memo:
作者单位:261031 潍坊医学院神经病学教研室(孟颖); 261031 潍坊医学院附属医院神经内科(庞萌,刘志辉)
通信作者:刘志辉,Email:lzhh1956@126.com
更新日期/Last Update: 2019-02-25